---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-064847"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:59:49.393498+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptose amends Hanmi acquisition deal; meeting moved to March 31, 2026 and gets $11.1M loan

## Summary
- Special shareholder meeting for Hanmi acquisition postponed from Jan 16 to March 31, 2026 due to SEC comments.
- Aptose enters $11.1M second amended facility with Hanmi; advances capped at $2M each, 6% interest, matures May 31, 2026.
- Facility funds clinical development of Tuspetinib for AML triplet therapy.
- Arrangement agreement restated to update meeting date; board unanimously recommends shareholders vote FOR.
- Facility is a related-party transaction exempt from formal valuation/minority approval due to financial hardship.

## SEC filing metadata
- accession: 0001193125-26-064847
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000119312526064847/0001193125-26-064847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000119312526064847/d70162d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-064847
- JSON: https://secwatch.observer/filing/0001193125-26-064847.json
- Plain text: https://secwatch.observer/filing/0001193125-26-064847.txt

## Key facts
- Debt Financings
  Aptose Biosciences Inc. amended credit facility of US$11.1 million with Hanmi Pharmaceuticals Co. Ltd. at six percent (6%) per annum.
  - Instrument: credit facility
  - Principal: US$11.1 million
  - Counterparty: Hanmi Pharmaceuticals Co. Ltd.
  - Rate: six percent (6%) per annum
  - Event: amendment
  source text: Second Amended and Restated Facility Agreement On February 23, 2026, the Company and Hanmi entered into a US$11.1 million second amended and restated facility agreement with Hanmi (the “ Second A&R Facility Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000119312526064847/0001193125-26-064847-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.